VEGF-D產(chǎn)品信息
英文名稱：Vascular endothelial growth factor D
中文名稱：血管內(nèi)皮生長因子D
靶點(diǎn)別稱：FIGF,VEGFD
物種：Human
標(biāo)簽：His Tag
屬性：Protein
標(biāo)記：Unconjugated
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human VEGF-D, His Tag (VED-H5228) is expressed from human 293 cells (HEK293). It contains AA Phe 93 - Ser 201 (Accession # AAH27948 ).
Predicted N-terminus: Phe 93
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 13.4 kDa. The protein migrates as 19-22 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
VEGF-D分子背景
Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.
VEGF-D用戶評價(jià)
關(guān)鍵字： VEGF-D;VEGF-D蛋白;血管內(nèi)皮生長因子D;FIGF;VEGFD;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。